Knight Therapeutics Inc. (TSX:GUD) will look for acquisition opportunities. Knight Therapeutics as filed a preliminary short form base shelf prospectus with securities regulatory authorities in each of the provinces of Canada. Following the acquisition of Biotoscana Investments S.A., Knight has access to more growth opportunities, including acquisitions of products as well as bolt on acquisitions of specialty pharmaceutical companies for its pan-American (ex US) footprint. The Shelf Prospectus provides Knight the financing flexibility without any incumbent obligation to use the instrument as it pursues larger opportunities.